אקסטנדי 40 מג טבליות
astellas pharma international b.v., israel - enzalutamide - טבליות מצופות פילם - enzalutamide 40 mg - enzalutamide
דביגטרן אס.קיי 110 מג
k.s.kim international ltd - dabigatran etexilate - קפסולות - dabigatran etexilate 110 mg - dabigatran etexilate
דביגטרן אס.קיי 150 מג
k.s.kim international ltd - dabigatran etexilate - קפסולות - dabigatran etexilate 150 mg - dabigatran etexilate
דביגטרן אס.קיי 75 מג
k.s.kim international ltd - dabigatran etexilate - קפסולות - dabigatran etexilate 75 mg - dabigatran etexilate
ניופוגן 30 mu בקבוקונים
amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu/ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).
ניופוגן mu 48 מזרק מוכן לשימוש
amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 48 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).
ניופוגן mu 30 מזרק מוכן לשימוש
amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).
ניולסטים
amgen europe b.v. - pegfilgrastim - תמיסה להזרקה - pegfilgrastim 10 mg/ml ml - pegfilgrastim - pegfilgrastim - reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy, given at intervals of 14 days or more, for malignancy. ( with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
וסומני
astellas pharma international b.v. - solifenacin succinate; tamsulosin hydrochloride - טבליות בשחרור מושהה - tamsulosin hydrochloride 0.4 mg; solifenacin succinate 6 mg - tamsulosin and solifenacin
אסופרים קונטרול 20 מג
k.s.kim international (sk- pharma) ltd., israel - esomeprazole as sodium - קפסולה קשיחה - esomeprazole as sodium 20 mg - esomeprazole